Advanced search
Publication Cover
International Journal of Cardiovascular Interventions Volume 4, 2001 - Issue 4
Journal homepage
86
Views
22
CrossRef citations to date
0
Altmetric
Research Article

The Lescol ® Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease

Patrick WJC Serruys Thoraxcenter, Erasmus University Hospital, Rotterdam, The Netherlands.
,
Pim J de Feyter University Hospital Rotterdam, Dijkzigt, The Netherlands.
,
Renée Benghozi Novartis Pharma AG, Basel, Switzerland.
,
Paul G Hugenholtz Emeritus Professor of Cardiology, Oosterbeek, The Netherlands.
&
Emmanuel Lesaffre Biostatistical Centre, Leuven, Belgium.
Pages 165-172 | Published online: 10 Jul 2009

  • Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Study (MRFIT). JAMA 1986; 256: 2823-2828.
  • Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990; 322: 1635-1641.
  • LaRosa JC, Hunninghake D, Grundy SM et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81: 1721-1733.
  • Neaton JD, Wentworth DF. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64.
  • Stamler J, Daviglus ML, Garside DB et al. Relationship of baseline cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and longevity. JAMA 2000; 284: 365-367.
  • Ornish D, Brown SE, Scherwitz LW et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; 336: 129-133.
  • Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.
  • Watts GF, Lewis B, Brunt JN et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563-569.
  • Blankenhorn DH, Azen SP, Kramsch DM et al. Coronary angiographie changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-976.
  • Brown BG, Zhao XQ, Sacco DE et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1791.
  • Frick MH, EIo O, Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged man with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
  • Herd JA, Ballantyne CM, Farmer JA et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study (LCAS). Am J Cardiol 1997; 80: 278-286.
  • Lipid Research Clinics Program. The Lipid Research Clinics Coronary Prevention Trial results 11: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
  • Mulder HJ, Bal ET, Jukema JW et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 2000; 86: 742-746.
  • National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 1994; 89: 1333-1445.
  • Rossouw JE. The effects of lowering serum cholesterol on coronary heart disease risk. Med Clin North Am 1994; 78: 181-195.
  • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
  • Sacks FM, Pfeffer MA, Moye LA et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
  • Serruys PW, Foley DP, Jackson G et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographie restenosis (FLARE) trial. Eur Heart J 1999; 20: 58-69.
  • Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MlRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
  • Dagres N, Erbel R. Comparison between PTCA and bypass operation. Results of large randomized studies. Med Klin 1998; 93: 22-26, 58.
  • Henderson RA, Pocock SJ, Sharp SJ et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina. Lancet 1998; 352: 1419-1425.
  • Ruygrok PN, de Jaegere PT, van Domburg RT et al. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. J Am Coll Cardiol 1996; 27: 1669-1677.
  • Jukema JW, Bruschke AV, van Boven AJ et al, on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
  • PyU+00F6rälä K, De Backer G, Graham I et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-1331.
  • Rules governing medicinal products in the European Community, Vol.III (addendum), July 1990: Guidelines for Good Clinical Practice and Directive 91/507/EEC.
  • World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organization 2001; 79: 373-374.
  • Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522-523 (letter).
  • Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410-414.
  • Friedewald WT, Levy Rl, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
  • EaSt (1992). A software package for the design and interim monitoring of group sequential clinical trials. Volume II: Application to Time to Failure Data. Cytel Software Corporation (Cambridge, Mass., USA).
  • SAS Technical Report P-229. SAS-STAT Software: Changes and Enhancements, Release 6.07, Gary, NC: SAS Institute Inc., 1992.
  • Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrics 1983; 70: 659-663.
  • O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
  • MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-638.
  • Long-Term Intervention with Pravastatin in lschaemic Disease (LlPlD) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
  • Ballantyne CM, Herd A, Ferlic LL et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99: 736-743.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.